If Pan02 cells develop pancreatic cancer depending on a Kras mutation, and if CIRT+HCQ‐treated tumors of KrasG12D isografts are impaired in Treg cell accumulation as well, we may be able to address how a Kras mutation is involved in this event precisely. This evidence concerns the gene KRAS and familial pancreatic carcinoma.